Table 3.
Univariate analysis of possible risk factors associated with non-albicans candidemia. Data are presented as number (percentage) unless otherwise specified.
| Variable | C. albicans | C. non-albicans | p-Value |
|---|---|---|---|
| Age (years, mean ± SD) | 68.55 ± 15.5 | 64.15 ± 17.9 | 0.111 |
| Female | 26 (43.3) | 58 (52.7) | 0.242 |
| Year of admission | |||
| 2004–2009 | 10 (16.7) | 20 (18.2) | 0.313 |
| 2010–2014 | 26 (43.3) | 35 (31.8) | |
| 2015–2019 | 24 (40.0) | 55 (50.0) | |
| Unit | |||
| Regular ward | 23 (38.3) | 53 (48.2) | 0.418 |
| Critical care unit | 33 (55.0) | 49 (44.5) | |
| Emergency department | 4 (6.7) | 8 (7.3) | |
| Diabetes mellitus | 17 (28.3) | 33 (30.0) | 0.820 |
| Hemodialysis patient | 13 (21.7) | 16 (14.5) | 0.238 |
| End-stage renal disease | 6 (10.0) | 4 (3.6) | 0.169 |
| Acute kidney injury | 7 (11.7) | 12 (10.9) | 0.881 |
| Solid organ transplant recipient | 0 (0.0) | 3 (100) | 0.553 |
| Stem cell transplant recipient | 1 (1.7) | 6 (5.5) | 0.423 |
| Auto-transplant | 1 (100) | 2 (33.3) | 0.459 |
| Allo-transplant | 0 (0.0) | 3 (50.0) | |
| Both | 0 (0.0) | 1 (16.7) | |
| Neutropenic | 6 (10.0) | 15 (13.6) | 0.628 |
| 1000–1500/mm3 | 2 (33) | 1 (6.7) | 0.219 |
| 500–1000/mm3 | 2 (33) | 4 (26.7) | |
| <500/mm3 | 2 (33) | 10 (66.7) | |
| Immunocompromised | 38 (63.3) | 72 (65.5) | 0.782 |
| Current steroids | 14 (23.3) | 22 (20.0) | 0.611 |
| Congenital syndromes | 2 (3.3) | 1 (0.9) | 0.285 |
| Other immunosuppressants | 2 (3.3) | 7 (6.4) | 0.495 |
| Malignancy | 27 (45.0) | 59 (53.6) | 0.282 |
| Non-hematologic | 21 (77.8) | 41 (69.5) | 0.729 |
| Hematologic | 5 (18.5) | 15 (25.4) | |
| Both | 1 (3.7) | 3 (5.1) | |
| Chemotherapy | 11 (18.3) | 27 (24.5) | 0.353 |
| <1 week from infection | 3 (27.3) | 7 (25.9) | 1.00 |
| Immunotherapy | 0 (0.0) | 3 (2.7) | 0.553 |
| Abdominal surgery within 30 days | 16 (26.7) | 29 (26.4) | 0.966 |
| Antibiotics within 30 days | 55 (91.7) | 106 (96.4) | 0.191 |
| Antifungal history | 10 (16.7) | 35 (31.8) | 0.032 * |
| Fluconazole | 6 (10.0) | 25 (22.7) | 0.040 * |
| Voriconazole | 0 (0.0) | 2 (1.8) | 0.541 |
| Amphotericin B | 1 (1.7) | 3 (2.7%) | 1.00 |
| Caspofungin | 3 (5.0) | 5 (4.5) | 1.00 |
| Anidulafungin | 0 (0.0) | 2 (1.8) | 0.541 |
| Duration of previous antifungal (days, mean ± SD) | 16.6 ± 24.8 | 16.7 ± 27.3 | 0.989 |
| Parenteral nutrition | 16 (26.7) | 28 (25.5) | 0.863 |
| Central venous catheter | 47 (78.3) | 70 (63.6) | 0.048 * |
| Source | |||
| CLABSI | 18 (30.0) | 22 (20.0) | 0.142 |
| Gastrointestinal translocation | 18 (30.0) | 39 (35.5) | 0.472 |
| Urinary tract infection | 6 (10.0) | 11 (10.0) | 1.00 |
| Unknown | 18 (30.0) | 36 (32.7) | 0.715 |
| Other | 0 (0.0) | 2 (1.8) | 0.528 |
CLABSI: Central Line-Associated Bloodstream Infection. *: p-values < 0.05.